SAHPRA

In terms of section 22C(1)(b) of the Medicines and Related Substances Act, 1965, the South African Health Products Regulatory Authority (“SAHPRA”) is allowed to issue licenses to qualifying applicants for the cultivation, manufacture, import and export of scheduled substances, such as cannabis, and is required to oversee and regulate these activities.

Compliance

All compliance and analysis tests are conducted by independent third-party laboratories that are SAHPRA licensed, experienced in dealing with cannabis products and adhere to WHO (World Health Organisation) and Pic/s (The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme) guidelines.

Standards

Calyx is committed to the highest standards of quality, sustainability and ethics in every area of our business, from cultivation and processing to procurement and talent development.

We have therefore adopted the following national and international standards to ensure that the business delivers value for stakeholders, and positive outcomes for our partner communities and the national economy in terms of foreign exchange earnings and taxation.

The application of these standards will ensure brand differentiation, quality control and traceability, and ultimately the long-term success of the business. This will contribute to the creation of employment opportunities and the development of viable subsidiary industries.

Obtaining such a license requires the applicant to demonstrate strict adherence to the guidelines outlined by SAHPRA, which includes compliance with Good Manufacturing Practice (“GMP”) and Good Agricultural and Collection Practice (“GACP”).
Calyx has been awarded a license by SAHPRA for the cultivation, processing, import and export of cannabis for the purpose of producing scheduled substances.